AR044283A1 - Procedimeinto para preparar compuestos de espirolactona - Google Patents
Procedimeinto para preparar compuestos de espirolactonaInfo
- Publication number
- AR044283A1 AR044283A1 ARP040101583A ARP040101583A AR044283A1 AR 044283 A1 AR044283 A1 AR 044283A1 AR P040101583 A ARP040101583 A AR P040101583A AR P040101583 A ARP040101583 A AR P040101583A AR 044283 A1 AR044283 A1 AR 044283A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- spirolactone
- group
- forming
- acid
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 229960002256 spironolactone Drugs 0.000 abstract 5
- -1 spirolactone ester Chemical class 0.000 abstract 4
- 239000002253 acid Substances 0.000 abstract 3
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 150000004820 halides Chemical class 0.000 abstract 2
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 239000011260 aqueous acid Substances 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Chemical group 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 230000002140 halogenating effect Effects 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000003301 hydrolyzing effect Effects 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 1: Un procedimiento para preparar un compuesto de la fórmula (1) o una sal del mismo, en el que: T, U, V y W se seleccionan cada uno independientemente del grupo que consiste en: nitrógeno; y metino; en los que el grupo metino no está sustituido o está opcionalmente sustituido con un sustituyente que se selecciona del grupo que consiste en: halógeno; alquilo inferior; hidroxi; y alcoxi inferior y en el que al menos dos de T, U, V y W son metino; que comprende las etapas de: a) formar un haluro de ácido de espirolactona de la fórmula (2), en el que X es cloro o bromo y T, U, V y W son tal como se define anteriormente, tratando el compuesto de la fórmula (1) con un agente de halogenación en un disolvente; b) formar un éster de espirolactona de la fórmula (3), en el que R3 se selecciona del grupo que consiste en terc-butilo, metilciclohexilo, metilciclopentilo y neopentilo y T, U, V y W son tal como se define anteriormente, tratando el haluro de ácido de espirolactona de la fórmula (2) con una base y un alcohol en un disolvente; c) formar un ácido de espirolactona de la fórmula (1), en el que T, U, V y W se definen como anteriormente, hidrolizando el éster de espirolactona de la fórmula (3) con un ácido acuoso; y d) aislar el producto resultante.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47168003P | 2003-05-19 | 2003-05-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR044283A1 true AR044283A1 (es) | 2005-09-07 |
Family
ID=33476871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040101583A AR044283A1 (es) | 2003-05-19 | 2004-05-10 | Procedimeinto para preparar compuestos de espirolactona |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20060241299A1 (es) |
| AR (1) | AR044283A1 (es) |
| AU (1) | AU2004240933A1 (es) |
| CA (1) | CA2526027A1 (es) |
| TW (1) | TW200510316A (es) |
| WO (1) | WO2004104009A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004043501A1 (de) * | 2004-09-06 | 2006-03-09 | Chemetall Gmbh | Methyllithium/Lithiumbromid enthaltendes Synthesemittel und Verfahren zu dessen Herstellung |
| WO2007016028A2 (en) | 2005-07-28 | 2007-02-08 | Merck & Co., Inc. | Synthesis and crystalline forms of npy5 antagonist |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI279402B (en) * | 1999-08-20 | 2007-04-21 | Banyu Pharma Co Ltd | Spiro compounds having NPY antagonistic activities and agents containing the same |
| CA2502282A1 (en) * | 2002-10-18 | 2004-05-06 | Merck & Co., Inc. | Process for making spirolactone compounds |
-
2004
- 2004-05-10 AR ARP040101583A patent/AR044283A1/es unknown
- 2004-05-14 CA CA002526027A patent/CA2526027A1/en not_active Abandoned
- 2004-05-14 US US10/550,136 patent/US20060241299A1/en not_active Abandoned
- 2004-05-14 AU AU2004240933A patent/AU2004240933A1/en not_active Abandoned
- 2004-05-14 WO PCT/US2004/015051 patent/WO2004104009A1/en not_active Ceased
- 2004-05-18 TW TW093114019A patent/TW200510316A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004240933A1 (en) | 2004-12-02 |
| US20060241299A1 (en) | 2006-10-26 |
| TW200510316A (en) | 2005-03-16 |
| WO2004104009A1 (en) | 2004-12-02 |
| CA2526027A1 (en) | 2004-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20030612A1 (es) | Benzoimidazoles | |
| ES474445A1 (es) | Proceso selectivo para la preparacion de derivados de la 7- hidroxi-cumarina | |
| CO6321144A2 (es) | Composiciones de peracido y 2-hidroxi acido organico y metodos para tratar productos agricolas | |
| CU23006A3 (es) | Nuevos ésteres derivados de compuestos fenil-ciclonuevos ésteres derivados de compuestos fenil-ciclohexil sustituidos hexil sustituidos | |
| CL2003002665A1 (es) | COMPUESTOS DERIVADOS DE ACIDOS CARBOXILICOS, SUS SALES; PROCEDIMIENTO DE PREPARACION; COMPOSICION FARMACEUTICA, Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES DONDE ES NECESARIO UN INHIBIDORE DEL FACTOR Xa Y /O UN INHIBIDOR DE SERINA PROTEASA. | |
| CY1108334T1 (el) | Υποκατασταθεισες δικετοπιπεραζινες ως ανταγωνιστες ωκυτοκινης | |
| ES2095529T3 (es) | Derivados de los acidos carboxilicos como inhibidores de la 5-alfa-reductasa. | |
| ATE331713T1 (de) | Verfahren zur herstellung von 5-nitrobenzofuranen | |
| ECSP034917A (es) | Nuevos derivados de acido sulfonico | |
| AR030203A1 (es) | Derivados de carbamato de 2-(s)-hidroximutilina, composiciones farmaceuticas que los comprenden, procedimiento para prepararlos y 2(s), 11-dihidroxi protegida-mutilina como compuesto intermediario | |
| PE20010678A1 (es) | Tratamiento de enfisema usando antagonistas retinoides selectivos de rar | |
| MXPA03004347A (es) | Nuevos derivados de imidazol, metodo de produccion y uso de los mismos. | |
| CO5720995A2 (es) | Compuesto novedoso | |
| DE602006021411D1 (de) | Verfahren zur herstellung von optional 2-substituierten 1,6-dihydro-6-oxo-4-pyrimidincarboxylsäuren | |
| ATE348825T1 (de) | Prozess zur herstellung von dioxanessigsäureestern | |
| ES2114721T3 (es) | Procedimiento para preparar intermedios derivados del acido benzoico y agentes farmaceuticos benzotiofenos. | |
| CO5700779A2 (es) | Un proceso para la preparación de oxi-(1h)-quinolin-2-onas 5-(haloacetil)-8-sustituidas | |
| AR044283A1 (es) | Procedimeinto para preparar compuestos de espirolactona | |
| ATE239722T1 (de) | Benzofurylpiperazine als serotonin-agonisten | |
| ECSP003680A (es) | Proceso para derivados del acido fenilacetico | |
| EA200401164A1 (ru) | Фунгицидные триазолопиримидины, способ их получения и их применение для борьбы с фитопатогенными грибами, а также содержащие их средства | |
| ATE9225T1 (de) | Derivate des 5-hydroxy-tetrahydro-2-furanons. | |
| GB1057349A (en) | Water-soluble flavanoid derivatives | |
| EA201071014A1 (ru) | Новые 7-замещенные производные 3-карбоксиоксадиазинохинолонов, способ их получения и применение в качестве антибактериальных средств | |
| AR016737A1 (es) | Procesos para preparar derivados indazol sustituidos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |